Drug maker Cipla has gained nearly 1.5% to Rs 572 on the BSE after the company on Monday announced commercial collaboration with UK-based S&D Pharma in the Czech Republic and Slovakia.
In a Bombay Stock Exchange (BSE) filing, Cipla said this collaboration will enable it to focus on its core therapy areas, while S&D Pharma will be the key partner for generics.
Under the collaboration, Cipla will drive its respiratory product portfolio in both Czech Republic and Slovakia through a Cipla-owned sales force team, managed by Cipla commercial head, the company said in a statement.
S&D Pharma will physically distribute all products, including respiratory products, and this portfolio will increase over the next few years, it added.
The stock opened at Rs 566, touched a high of Rs 573 and a low of Rs 566 on the BSE. A total of 18,030 shares have been exchanged on the BSE so far.
